Moderna Reports Excellent Results From Coronavirus Vaccine Booster Trial

In a fresh shot of good news in the global battle against the coronavirus pandemic, Moderna (NASDAQ:MRNA) Wednesday reported highly encouraging preliminary results from a booster vaccine study.

The phase 2 study measured the efficacy of booster shots of the company's mRNA-1273 coronavirus vaccine. Two boosters were administered for the trial, one containing the original mRNA-1273, and another (mRNA-1273.351) specifically designed to combat the apparently more threatening South African variant of the coronavirus. In both cases, the boosters increased the body's production of neutralizing antibodies.